Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

FDA widens Tylenol probe

By Parija Kavilanz, senior writer


NEW YORK (CNNMoney.com) -- The Food and Drug Administration said Monday it is expanding its investigation of a Johnson & Johnson manufacturing division tied to the recent recall of children's drugs.

On May 1, Johnson & Johnson's McNeil Consumer Healthcare unit recalled some 50 children's versions of non-prescription drugs, including Tylenol, Motrin and Benadryl.

Then on May 6, the FDA issued a scathing 17-page inspection report of McNeil's Fort Washington, Pa., plant that produced the drugs.

Now the FDA is conducting a companywide investigation of McNeil's "manufacturing practices to determine whether similar problems exist throughout the company and what additional steps the agency must take to ensure that these problems do not recur," according to a statement posted Monday on the FDA website.

In a statement e-mailed to CNNMoney on Monday, McNeil said the company "is conducting a comprehensive quality assessment across its manufacturing operations and continues to cooperate with the FDA."

Johnson & Johnson (JNJ, Fortune 500), which subsequently shut the Fort Washington facility, has declined to disclose what other products are manufactured at the plant.

In announcing the recall, McNeil said that some of the children's products may contain incorrect concentration of ingredients, ingredients that don't meet testing requirements and tiny metal particles.

The FDA on Monday declined to comment on how many other facilities it is targeting in the expanded probe.

A McNeil plant in Puerto Rico that makes adult versions of over-the-counter drugs was the focus of a recall in January after the company got complaints of an "unusual moldy, musty or mildew-like" odor in products made at the plant.

The FDA's May 6 report about the Fort Washington plant listed 20 violations. In one of them, the agency said McNeil had taken no action after receiving 46 consumer complaints on the recalled products.

The company and the FDA have said that the recalled children's drugs pose a "remote" potential for serious health problems.

A congressional committee has opened an investigation into the recall.

The House Committee on Oversight and Government Reform has scheduled a hearing on May 27 to examine the recall. The panel said it had invited Johnson & Johnson Chief Executive William Weldon to testify.

Johnson & Johnson spokesman Jeff Leebaw said the drugmaker is "communicating with the committee and will respond appropriately to its request."  To top of page

Index Last Change % Change
Dow 15,973.84 313.66 2.00%
Nasdaq 4,337.51 70.67 1.66%
S&P 500 1,864.78 35.70 1.95%
Treasuries 1.75 0.10 6.33%
Data as of 3:38am ET
Company Price Change % Change
Bank of America Corp... 11.95 0.79 7.08%
General Electric Co 28.26 0.81 2.95%
Cisco Systems Inc 25.11 0.43 1.74%
Chesapeake Energy Co... 1.59 -0.19 -10.67%
Freeport-McMoRan Inc... 5.53 0.64 13.09%
Data as of Feb 12
Sponsors

Sections

Investors need someone they can bring home to mother instead of bad boys (or girls) that may make their heart beat faster. Boring beats bold in this market. Here are 10 dependable stocks we love. Southwest (ticker symbol: LUV) is one. More

India's finance minister isn't worried about jobs being lost in the country's manufacturing sector despite warnings that industrial robots will dramatically reduce the need for factory workers in coming decades. More

Eastern Illinois University laid off 198 staff members this week, and the college president is blaming the state government. More